Suppr超能文献

病例报告:原发性心脏血管肉瘤的全外显子组测序凸显了靶向治疗的潜力。

Case report: whole exome sequencing of primary cardiac angiosarcoma highlights potential for targeted therapies.

作者信息

Zhrebker Leah, Cherni Irene, Gross Lara M, Hinshelwood Margaret M, Reese Merrick, Aldrich Jessica, Guileyardo Joseph M, Roberts William C, Craig David, Von Hoff Daniel D, Mennel Robert G, Carpten John D

机构信息

Baylor Charles A. Sammons Cancer Center at Dallas, Baylor University Medical Center at Dallas, 3410 Worth Street, Dallas, TX, 75246, USA.

Department of Internal Medicine, Baylor University Medical Center at Dallas, 3500 Gaston Ave, Dallas, TX, 75246, USA.

出版信息

BMC Cancer. 2017 Jan 5;17(1):17. doi: 10.1186/s12885-016-3000-z.

Abstract

BACKGROUND

Primary cardiac angiosarcomas are rare, but they are the most aggressive type of primary cardiac neoplasms. When patients do present, it is with advanced pulmonary and/or cardiac symptoms. Therefore, many times the correct diagnosis is not made at the time of initial presentation. These patients have metastatic disease and the vast majority of these patients die within a few months after diagnosis. Currently the treatment choices are limited and there are no targeted therapies available.

CASE PRESENTATION

A 56-year-old male presented with shortness of breath, night sweats, and productive cough for a month. Workup revealed pericardial effusion and multiple bilateral pulmonary nodules suspicious for metastatic disease. Transthoracic echocardiogram showed a large pericardial effusion and a large mass in the base of the right atrium. Results of biopsy of bilateral lung nodules established a diagnosis of primary cardiac angiosarcoma. Aggressive pulmonary disease caused rapid deterioration; the patient went on hospice and subsequently died. Whole exome sequencing of the patient's postmortem tumor revealed a novel KDR (G681R) mutation, and focal high-level amplification at chromosome 1q encompassing MDM4, a negative regulator of TP53.

CONCLUSION

Mutations in KDR have been reported previously in angiosarcomas. Previous studies also demonstrated that KDR mutants with constitutive KDR activation could be inhibited with specific KDR inhibitors in vitro. Thus, patients harboring activating KDR mutations could be candidates for treatment with KDR-specific inhibitors.

摘要

背景

原发性心脏血管肉瘤罕见,但却是原发性心脏肿瘤中侵袭性最强的类型。患者出现症状时,多伴有晚期肺部和/或心脏症状。因此,很多时候在初次就诊时无法做出正确诊断。这些患者患有转移性疾病,绝大多数患者在诊断后数月内死亡。目前治疗选择有限,且没有可用的靶向治疗方法。

病例报告

一名56岁男性出现气短、盗汗和咳痰1个月。检查发现心包积液和多个双侧肺结节,怀疑为转移性疾病。经胸超声心动图显示大量心包积液和右心房底部有一个大肿块。双侧肺结节活检结果确诊为原发性心脏血管肉瘤。严重的肺部疾病导致病情迅速恶化;患者进入临终关怀,随后死亡。对患者死后肿瘤进行的全外显子组测序发现了一种新的KDR(G681R)突变,以及1号染色体q臂上包含MDM4(一种TP53负调节因子)的局灶性高水平扩增。

结论

先前在血管肉瘤中已报道过KDR突变。先前的研究还表明,具有组成性KDR激活的KDR突变体在体外可被特定的KDR抑制剂抑制。因此,携带激活型KDR突变的患者可能是KDR特异性抑制剂治疗的候选对象。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d777/5217318/939bbe9c517b/12885_2016_3000_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验